M. Woerns

发表

Inclusion of targeted therapies in the standard of care for metastatic colorectal cancer patients in a German cancer center: the more the better?!

P. Galle, J. Marquardt, T. Thomaidis, 2015, Journal of Cancer Research and Clinical Oncology.

Urinary ethyl glucuronide (uEtG) as a marker for alcohol consumption in liver transplant candidates: a real-world cohort

P. Galle, K. Lackner, J. Marquardt, 2020, Zeitschrift für Gastroenterologie.

Efficacy, safety, tolerability, and PK of the HDAC inhibitor resminostat in sorafenib-refractory hepatocellular carcinoma (HCC): Phase II SHELTER study.

G. Gerken, A. Santoro, V. Zagonel, 2012 .

Gemcitabine plus sorafenib versus gemcitabine alone in advanced biliary tract cancer: a double-blind placebo-controlled multicentre phase II AIO study with biomarker and serum programme.

F. Lammert, P. Galle, F. Kolligs, 2014, European journal of cancer.

Safety and efficacy of afatinib as add-on to standard therapy of gemcitabine/cisplatin in chemotherapy-naive patients with advanced biliary tract cancer: an open-label, phase I trial with an extensive biomarker program

P. Galle, J. Marquardt, C. Ruckes, 2019, BMC Cancer.

Durability of treatment response after 1 year of therapy with seladelpar in patients with primary biliary cholangitis (PBC): final results of an international phase 2 study

S. Bergheanu, T. Hassanein, B. Bacon, 2020, Journal of Hepatology.

Tu1476 – Afatinib Combined with Gemcitabine/Cisplatin in Chemotherapy Naive Patients with Advanced Biliary Tract Cancer: Results and Translational Analysis of an Open-Label, Phase I Trial

P. Galle, J. Marquardt, C. Ruckes, 2019, Gastroenterology.

Safety and efficacy of afatinib as add-on to standard therapy of gemcitabine/cisplatin in chemotherapy-naive patients with advanced biliary tract cancer: an open-label, phase I trial with an extensive biomarker program

P. Galle, J. Marquardt, C. Ruckes, 2019, BMC Cancer.

Validation of insulin-like growth factor-1 as a prognostic parameter in patients with hepatocellular carcinoma in a European cohort

P. Galle, I. Schmidtmann, C. Labenz, 2018, BMC Cancer.

Nab-paclitaxel/gemcitabine first-line therapy in patients with metastatic pancreatic carcinoma and high-bilirubin levels: Data from the German QoliXane Pancreatic Cancer Registry.

M. Stauch, R. Hofheinz, J. Roemmler-Zehrer, 2016 .

Resminostat in advanced hepatocellular carcinoma (HCC): Overall survival subgroup analysis of prognostic factors in the SHELTER trial.

A. Santoro, M. Scheulen, E. Giannini, 2013 .

A randomized, double-blind, multicenter phase II AIO trial with gemcitabine plus sorafenib versus gemcitabine plus placebo in patients with chemotherapy-naive advanced or metastatic biliary tract cancer: First safety and efficacy data.

F. Lammert, S. Zeuzem, F. Kolligs, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Management of Hepatic Sarcoidosis.

M. Ebert, P. Galle, A. Teufel, 2022, Journal of Gastrointestinal and Liver Diseases.